Elizabeth Dudnik retweeted
Excellent presentation by @DrMarkAwad of exploratory neoadj nivo-ipi arm vs chemo of #cm816. Improved pCR, EFS and trend toward improved OS. Striking early crossing of EFS curves suggests chemo is still needed in this setting.
Elizabeth Dudnik retweeted
#ESMO23 Dr. @DoctorJSpicer presents OS data from KEYNOTE 671: neoadjuvant pembrolizumab + chemotherapy followed by surgery and adjuvant pembro x 1 year. Perioperative IO improves survival. OS HR 0.72, 3y OS rate 71% vs 64%, impressive tails. Now an FDA approved standard.
Elizabeth Dudnik retweeted
#ESMO23 RR 63% with pembrolizumab + adagrasib in PDL1 high NSCLC. Median time to response 1.4m. mDOR and mPFS not yet reached. Single arm study but recall RR with pembro in KEYNOTE 024 was 44.8%. Certainly warrants a phase III study.
Elizabeth Dudnik retweeted
#ESMO23 Included 54 pts with PD-L1 high NSCLC. Balanced arms. Only 6% discontinuation of adagrasib from TRAEs. Treatment related hepatic events in < 10% of adagrasib + pembrolizumab arm. Very reassuring. Why different from sotorasib? PK difference? Binding differences?
Elizabeth Dudnik retweeted
#WCLC23 Presidential Session🔥
Incredible presentation by Erik Lim 🇬🇧 of the Ph III MARS2 trial of Surgery v No surgery in mesothelioma:
- no OS benefit
- poorer QOL
- higher toxicity
Critical study. Congrats to all authors @iaslc @OncoAlert #LCSM
Elizabeth Dudnik retweeted
🌟 Combining Stereotactic Ablative Radiotherapy (SABR) with immunotherapy (I-SABR) shows a significant boost in 4-year event-free survival rates, compared to SABR alone.
🔘Fewer relapses, promising safety profile, and a potential game-changer for patients with early-stage NSCLC.
🔘Awaiting further results from ongoing trials for confirmation. 🎗️💊
@TheLancet @OncoAlert @OncBrothers @IASLC
#lungcancer #Immunotherapy
Elizabeth Dudnik retweeted
Phase III IPSOS trial @TheLancet: first-line atezolizumab (anti-PDL1) monotherapy to single agent chemotherapy in 453 pts ineligible for platinum-doublet (PS 2-3 or age plus comorbidities). QoL and survival favored atezolizumab (HR 0.78, 2y OS 24% vs 12%).
thelancet.com/journals/lance…
Elizabeth Dudnik retweeted
Astra and Daiichi say that their TROP2 ADC hit on PFS at interim in the anticipated phase 3 NSCLC trial but that OS needs to mature further. No data provided today. astrazeneca.com/media-centre…
Elizabeth Dudnik retweeted
First snapshots of Aegean data, periadjuvant phase 3 trial in resectable lung cancer. Neoadjuvant chemo-Durva then surgery then adj Durva vs neoadj chemo alone then surgery. Looking forward to digging into these data! Does adj year of PD-L1 blockade add to neoadj alone? #LCSM
This quoted post is unavailable.
Elizabeth Dudnik retweeted
Not enough attention has been paid to chronic fatigue and out of hours working amongst health professionals and its impact on their safety and of others- these data do not surprise me - I have heard many stories over 25yrs of fatal accidents likely resulting from night work
Elizabeth Dudnik retweeted
Altogether, this suggests a mechanistic and causative link between air pollutants triggering expansion of pre-existing mutant cells in normal tissues via a clinically actionable inflammatory axis. (Thanks @Biorender)
Elizabeth Dudnik retweeted
Tumour promotion was first proposed by Berenblum & Shubik and developed by Allan Balmain and others. Thank you to Prof Balmain for this excellent N&V nature.com/articles/d41586-0…
Elizabeth Dudnik retweeted
Today our important study on air pollutants in the promotion of lung cancer has been published in @Nature led by @WillHilliam @LimEmilia @DrClareWeeden @SwantonLab ...Thread below🧵nature.com/articles/s41586-0…
Elizabeth Dudnik retweeted
#ELCC Day 1 Highlight: Amivantamab long-term outcomes + biology in EGFR exon20ins+ NSCLC:
- 48% pts have clinical benefit at 1yr
- 47.2% pts alive at 2yrs
- Baseline ctDNA alteratns in RAS/RAF/MEK assoc with less time on tx
@myESMO @Piuchagarrido #LCSM
dailyreporter.esmo.org/europ…
Elizabeth Dudnik retweeted
#ELCC23
3-yr Update of CM816 trial: Neoadj chemoIO v chemo shows
- contd EFS benefit
- OS HR 0.67 (p=0.012)
- *chemoIO appears to protect against CNS progression* - this is the gold
Impressive data. Identifying what further IO adds, is the key quesn
@myESMO @FordePatrick #LCSM
Elizabeth Dudnik retweeted
CM816 trial 👑: Neoadjuvant chemo + IO improved 3-year EFS vs neoadj Ch alone with lowe 🧠 recurrences with chemoIO approach💡Challenges: Do we need ADJ IO after the neoadj CT+IO approach?Role of this strategy in stage I/II NSCLC? In stage III: CM816 vs PACIFIC? @myESMO #ELCC2023
Elizabeth Dudnik retweeted
Die dazugehörige Publikation in Zusammenarbeit mit @AurelieSwalduz @Alfdoc2 @lungendoc @hausruck1
@_SayedHashemi @ElizabethDudnik @lungcancerpall @JairBar4
@ZerAlona und anderen finden Sie unter doi.org/10.1177/175883592211…
Elizabeth Dudnik retweeted
#CodeBreaK200 study for pts with #KRASG12C-mut platinum/IO pretreated #NSCLC
🎯Sotorasib (oral KRASG12C inhibitor) showed superiority over docetaxel!
✅1y-PFS: 24.8 vs 10.1% (HR=0.66; P=0.002)
✅ORR: 28.1 vs 13.2%
⬇️grade≥3 TRAEs
Congrats @MLJohnsonMD2 & team!
#ESMO22 @OncoAlert
